The Future Through Bio and Nano Technologies

Hydrogen Bioreactors, BioNanoChannel(TM) Diagnostics, and Bioremediation.

NanoLogix, Inc. (Stock Symbol NNLX.pk) is an industry innovator in the research, development, and commercialization of Nano-biotechnology.  The Company has developed and owns or has rights to over 30 patents. The Company has filed additional patent applications for discoveries related to hydrogen bioreactors, medical testing and  Rapid BioNanoChannel(TM) Microorganism Diagnostics Technology.

All of NanoLogix's patents and technologies are in the biotech and medical sectors.  NanoLogix-developed patents are used to design and market diagnostic test kits for use in early detection of infectious and noninfectious human diseases such as tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic fibrosis. 

NanoLogix believes that BioNanoChannel™ technology has the potential to capture much of the current worldwide Petri dish market --- a market with a multi-billion dollar annual value.

Please contact us for more information

 

Recent.Highlights

Tuesday, April 8: NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director.

Monday, March 31: NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update.

Friday, March 28: 4Q Financials are published to complement the 1Q - 3Q financials presented in October of 2007.

Sunday, March 16: Click here to listen to a radio interview with Bret Barnhizer, CEO & President of NanoLogix, Inc. and Marlene Bourne of Bourne Research. (Look for "March 16, Hydrogen Power" interview on linked page.)

Monday, February 25: Designer Diagnostics Begins Marketing First Ever Environmental Test Kit for the Detection of Nontuberculous Mycobacteria.

Tuesday, February 12: National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welch's Foods

Press Release Archives